Literature DB >> 15809755

Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.

Keiji Suga1, Tetsuhisa Yamamoto, Yoshitaka Yamada, Shin-Ichi Miyatake, Toshimasa Nakagawa, Nobuhiko Tanigawa.   

Abstract

Survivin, a novel member of the inhibitor of apoptosis protein (IAP) family, has been markedly overexpressed in most types of human carcinoma, and recognized as a potential target in anticancer therapy. In addition, two splice variants of survivin, survivin-2B and survivin-deltaEx3, have recently been identified. However, expression analysis on its splice variants has not been reported in colorectal carcinomas. Therefore, we investigated the transcription levels of survivin and its splice variants in human colorectal carcinomas, and the correlation between transcript expression levels and pathological findings was analyzed. Tumor tissue samples were provided from 52 cases with colorectal adenocarcinoma resected at the Osaka Medical College from 1995 to 1996. Transcription levels were measured by performing quantitative reverse transcription-polymerase chain reaction (RT-PCR) using primer pairs specific for survivin and either of its splice variants, then normalized by the glyceraldehyde 6-phosphate dehydrogenase. The transcription levels of survivin and its splice variants were significantly higher in the tumor tissue samples, and significantly lower in the normal tissue samples. In addition, approximately 40% of the normal tissue samples did not have any survivin expression. The relative expression level of survivin-2B to survivin (survivin-2B/survivin) was significantly higher in the tumor tissue samples than in the normal ones. In contrast, survivin-deltaEx3/survivin revealed no difference between tumor and normal samples. When Comparing the histological disease stages (stage I and II vs. stage III and IV), there were no significant differences in the expression levels of survivin and its splice variants. The expression level of survivin-2B/survivin for stage III and IV was lower than the one for stage I and II. In addition, a higher level of survivin-2B/survivin significantly correlated with a better prognosis in the present series. The present study demonstrates high expression level of survivin and its splice variants, which is relatively specific in tumor tissue and suggests that they have important roles in the progression of human colorectal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809755

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

1.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

Review 2.  Survivin study: an update of "what is the next wave"?

Authors:  Fengzhi Li; Xiang Ling
Journal:  J Cell Physiol       Date:  2006-09       Impact factor: 6.384

3.  Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma.

Authors:  Salvatore De Maria; Giuseppe Pannone; Pantaleo Bufo; Angela Santoro; Rosario Serpico; Salvatore Metafora; Corrado Rubini; Daniela Pasquali; Silvana M Papagerakis; Stefania Staibano; Gaetano De Rosa; Ernesto Farina; Monica Emanuelli; Andrea Santarelli; Maria Ada Mariggiò; Lucio Lo Russo; Lorenzo Lo Muzio
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-19       Impact factor: 4.553

4.  Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.

Authors:  Tiffany Doucette; Khatri Latha; Yuhui Yang; Gregory N Fuller; Arvind Rao; Ganesh Rao
Journal:  Neuro Oncol       Date:  2014-03-27       Impact factor: 12.300

Review 5.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

6.  The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.

Authors:  Anna G Antonacopoulou; Konstantina Floratou; Vasiliki Bravou; Anastasia Kottorou; Fotinos-Ioannis Dimitrakopoulos; Stella Marousi; Michalis Stavropoulos; Angelos K Koutras; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

7.  Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.

Authors:  Anastasia Pavlidou; Maria Dalamaga; Christos Kroupis; George Konstantoudakis; Maria Belimezi; George Athanasas; Kleanthi Dimas
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

Review 8.  Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment.

Authors:  M Zhang; J Yang; F Li
Journal:  J Exp Clin Cancer Res       Date:  2006-09

9.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

10.  Survivin expression in colorectal carcinomas: correlations with clinicopathological parameters and survival.

Authors:  J G Kalliakmanis; Ch Kouvidou; C Latoufis; G Kouvatseas; D Anagnostakis; G Papatheodoridis; J Koskinas; A Archimandritis
Journal:  Dig Dis Sci       Date:  2009-12-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.